HLX04 vs Zirabev (bevacizumab-bvzr)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

HLX04 · Hanbeitai

Marketed by Shanghai Henlius Biotech

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03952403 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.

Reported efficacy

Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)

Result source: NCT03952403

Zirabev (bevacizumab-bvzr)

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02364999 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.

Reported efficacy

Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)

Result source: NCT02364999

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHLX04Zirabev (bevacizumab-bvzr)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999
Duration of response, median—Not reported8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999

PFS, median

HLX04
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

OS, median

HLX04
—Not reported
Zirabev (bevacizumab-bvzr)
—Not reported

ORR

HLX04
—Not reported
Zirabev (bevacizumab-bvzr)
45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999

Duration of response, median

HLX04
—Not reported
Zirabev (bevacizumab-bvzr)
8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HLX04
ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. NCT03952403 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HLX04: 0 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZirabev (bevacizumab-bvzr)
Dropout rate
46.1%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
22.8%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
alopecia 46.6%
anaemia 28.7%
fatigue 20.5%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zirabev (bevacizumab-bvzr)

ORR 45.3% (n=358) vs 44.6% (n=361) Bevacizumab-EU @ 25wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 8.38 vs 6.62 Bevacizumab-EU months
time to event · months
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to months from 36.3 weeks as posted
PFS 32.3% (n=358) vs 30.5% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 65.8% (n=358) vs 64.1% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX04's landscape · Zirabev (bevacizumab-bvzr)'s landscape